Coronary revascularization guided by fractional flow reserve (FFR) is associated with better patient outcomes after the procedure than revascularization guided by angiography alone. It is unknown whether the instantaneous wave-free ratio (iFR), an alternative measure that does not require the administration of adenosine, will offer benefits similar to those of FFR.
Use of Instantaneous Wave-free R atio in PCI F or the past 20 years, physiological measurements obtained during invasive procedures have been used to guide coronary revascularization. Pioneering work supported the use of flow measurements to make safe decisions about revascularization, 1,2 but this approach was soon superseded by the use of fractional flow reserve (FFR), which measures pressure as a surrogate of flow to estimate the severity of stenosis. [3] [4] [5] FFR was successful largely because of its technical simplicity and because clinical trials showed that it was associated with improved clinical outcomes after percutaneous coronary intervention (PCI). 6, 7 Consequently, FFR is now included in the appropriate-use criteria for coronary angiography and in the American College of Cardiology-American Heart Association-European Society of Cardiology guidelines; despite these recommendations, its adoption remains limited. [8] [9] [10] FFR must be measured during maximal hyperemia, which is typically induced with the administration of a potent intravenous or intracoronary vasodilator, such as adenosine. 11 Several studies have questioned the need for the administration of a vasodilator to assess stenosis severity. [12] [13] [14] In these studies, investigators found that in determining stenosis severity, FFR was not superior to the instantaneous wave-free ratio (iFR), a pressurederived index of stenosis severity that is not obtained with the administration of a vasodilator. We aimed to determine the efficacy and safety of an iFR-guided strategy versus an FFR-guided strategy for coronary revascularization.
Me thods

Trial Design and Management
DEFINE-FLAIR (Functional Lesion Assessment of
Intermediate Stenosis to Guide Revascularisation) is a multicenter, international, randomized, blinded trial in which iFR is being compared with FFR for physiologically guided coronary revascularization. The trial, which is ongoing, is being performed at 49 interventional sites across 19 countries on 4 continents. The 1-year outcomes, on which the primary trial analysis is based, are reported here.
The trial was designed by the steering committee (for a list of committee members, see the Supplementary Appendix, available with the full text of this article at NEJM.org). Central ethics approval was granted by the National Research Ethics Service Committee London, and local ethics approval was granted at each participating site. The trial is funded by an unrestricted educational grant from Philips Volcano, which had no role in the design of the trial, the collection or analysis of the data, the writing of the manuscript, or the decision to submit the manuscript for publication.
Trial management and oversight were performed by personnel at the Imperial College Trials Unit, Imperial College London, who maintained the clinical database and conducted all the data analyses independent of the funder. A risk assessment established that the trial was of low risk to the patients; therefore, no data and safety monitoring board was established. The first draft of the manuscript was written by the first author, and all the authors participated in trial oversight, approved all subsequent drafts of the manuscript, and made the decision to submit the manuscript for publication. The steering committee and all the authors vouch for the accuracy and completeness of the data and analyses and for the fidelity of the study to the trial protocol and statistical analysis plan, which are available at NEJM.org.
Population
Patients who had undergone coronary angiography were assessed for trial eligibility. Patients were eligible for inclusion in the trial if they had coronary artery disease with at least one native artery in which the stenosis was of questionable physiological severity (typically, an artery with 40 to 70% stenosis of the diameter on visual assessment). Patients with tandem stenoses (i.e., stenoses separated by more than 10 mm within a single vessel) that would require independent evaluation and treatment were excluded. A full list of inclusion and exclusion criteria is provided in Table S1 in the Supplementary Appendix. No exclusions were made on the basis of heart rate or rhythm. Written informed consent was obtained from all the patients before their enrollment in the trial.
Randomization
Eligible patients were randomly assigned to undergo revascularization guided by either FFR or iFR. Randomization was performed with the use of an automated and validated online randomization tool (SRUB, Imperial College London). During the trial procedures, investigators were allowed to obtain FFR or iFR measurements only T h e ne w e ngl a nd jou r na l o f m e dicine in accordance with group assignment. Verification of the data was performed in each patient with the use of the electronic physiology record, which was uploaded directly from the physiological console for each patient into the electronic clinical record (Fig. S1 in the Supplementary Appendix). During the procedure, patients were not told which technique was used for physiological assessment, and they remained unaware of their group assignment throughout the entire course of the trial. The research nurses and doctors who were responsible for the follow-up visits were also unaware of the group assignments.
Procedure
Before the FFR or iFR measurement was obtained, intracoronary nitrates were administered to control vasomotor tone. The physiological measurements were obtained in the routine manner with the use of a coronary-pressure guidewire (Philips Volcano) (Figs. S1 and S2 in the Supplementary Appendix). Physiological assessment was performed in all vessels with questionable stenosis severity. In patients with an acute coronary syndrome, physiological assessment was performed in only nonculprit vessels, after the culprit vessel had been revascularized. Prespecified treatment thresholds were an FFR of 0.80 and an iFR of 0.89 (Fig. S3 in the Supplementary Appendix). When the FFR or iFR for a given stenosis was equal to or lower than the prespecified threshold, the stenosis was revascularized with a drug-eluting stent or a bioresorbable vascular scaffold or by coronary-artery bypass grafting (CABG). When the FFR or iFR was higher than the prespecified threshold, treatment was deferred. When multivessel revascularization was attempted, investigators could choose to prespecify a staged treatment plan, with the staged procedure performed within 60 days. Adverse procedural signs and symptoms were documented.
Routine clinical follow-up assessments were performed at 30 days and at 1 year, and followup by telephone was conducted at 6 months. Complete monitoring of every electronic clinical record was performed, and the data were confirmed by on-site source-document verification in a randomly selected 30% of patients.
End Points
The primary end point was the 1-year risk of major adverse cardiac events, which were a composite of death, nonfatal myocardial infarction, or unplanned revascularization. Death was considered to be from cardiovascular causes unless an unequivocal noncardiovascular cause was established. Myocardial infarction was classified as either spontaneous or periprocedural and as either ST-segment elevation myocardial infarction (STEMI) or non-STEMI (NSTEMI). Revascularization was considered to be unplanned when it was not the index procedure and was not identified at the time of the index procedure as a staged procedure to occur within 60 days. Detailed endpoint definitions, which did not change after the commencement of the trial, are provided in the Supplementary Appendix.
End-point events were adjudicated with the use of anonymized source documentation by a committee of international experts who were not part of the steering committee. A consensus decision was made on the basis of prespecified end-point definitions. Members of the events committee remain unaware of the identities of the patients and their group assignments.
Statistical Analysis
The prespecified trial hypothesis was that iFR would be noninferior to FFR with respect to the risk of major adverse cardiac events at 1 year among patients undergoing physiologically guided revascularization. We based the sample size on an assumed annual rate of primary end-point events of 8.5% in a population that includes a mix of patients with either stable coronary disease or acute coronary syndromes 15 ; given this rate, we calculated that a sample size of 2305 patients would provide the trial with 90% power to detect the noninferiority of iFR to FFR, with the use of a noninferiority margin of 3.4 percentage points for the difference in risk, at a type I error rate of 5%. To allow for attrition, the target sample size was set at 2500 patients.
Both a risk-difference analysis and a time-toevent analysis were performed. The time-to-event analysis was conducted with the use of the Kaplan-Meier method. A Cox survival model was used to derive hazard ratios. For the results of both analyses, two-sided 95% confidence intervals (whose upper limits correspond to the upper limits of one-sided 97.5% confidence intervals) and two-sided 99% confidence intervals (whose upper limits correspond to the upper limits of one-sided 99.5% confidence intervals) are reported. The validity of the proportional-Use of Instantaneous Wave-free R atio in PCI hazards assumption was tested with Schoenfeld residuals. There were no signs of violation of the proportional-hazards assumption.
Patients who withdrew from the study before they reached 1 year of follow-up and who were event-free at their last visit were excluded from the risk-difference analysis for the primary end point and its components. Data for these patients were censored at the time of withdrawal for the time-to-event analysis. Patients who had a myocardial infarction or an unplanned revascularization before withdrawing from the study were included in the risk-difference analysis.
R esult s
Patients and Procedures
During the recruitment period (January 2014 to December 2015), a total of 2535 patients who underwent coronary angiography were assessed for trial eligibility. Of the 2492 patients who met the enrollment criteria, 1242 were assigned to the iFR group and 1250 to the FFR group (Fig. 1) . The baseline demographic characteristics of the patients are shown in Table 1 . The mean age of the patients was 65 years, 76% were men, and 80% had stable coronary artery disease.
Procedural characteristics for the two trial groups are shown in Figure 1 and Table 2 . A total of 99.4% of the patients assigned to the iFR group and 99.6% of those assigned to the FFR group underwent the assigned procedure. Crossover, which represented a deviation from the protocol, occurred in 13 cases and was due to profound early adenosine-induced bradycardia and hypotension in 1 case and to site errors in the remaining 12 cases. There were no cases in which heart-rhythm disturbances or lack of electrocardiographic assessment prevented FFR or iFR measurements from being obtained.
The number of vessels evaluated did not differ significantly between the iFR group and the FFR group (total number assessed, 1575 and 1608, respectively; mean [±SD] number evaluated per patient, 1.27±0.61 and 1.29±0.63; P = 0.58). The mean iFR and FFR measurements were close to their respective thresholds (mean iFR, 0.91±0.09; mean FFR, 0.83±0.09); these findings suggest that most of the assessed vessels had stenosis of intermediate severity (Figs. S4 and S5 in the Supplementary Appendix). The number of functionally significant stenoses (i.e., stenoses with an iFR or FFR below the treatment threshold) was significantly lower in the iFR group than in the FFR denotes fractional flow reserve, and iFR instantaneous wave-free ratio. * Plus-minus values are means ±SD. There were no significant differences between the two groups in baseline characteristics. To convert the values for cholesterol to milligrams per deciliter, divide by 0.02586. FFR denotes fractional flow reserve, iFR instantaneous wave-free ratio, and STEMI ST-segment elevation myocardial infarction. † In patients with STEMI or an acute coronary syndrome, only nonculprit lesions were evaluated. Patients with STEMI were evaluated more than 48 hours after the event occurred. ‡ In the New York Heart Association (NYHA) functional classification system, classes range from I to IV, with higher classes indicating greater limitations of physical activity owing to heart disease. § In the Canadian Cardiovascular Society (CCS) functional classification system, classes range from I to IV, with higher classes indicating greater limitations of physical activity owing to angina. ¶ The body-mass index is the weight in kilograms divided by the square of the height in meters. In both the iFR group and the FFR group, the number of patients who underwent PCI (565 and 625, respectively) was greater than the number who had functionally significant stenoses (426 and 486, respectively). This is because PCI procedures that were performed in culprit vessels of patients with an acute coronary syndrome and in angiographically significant stenoses (neither of which required physiological assessment) were included in the totals. The median procedure time was significantly shorter in the iFR group than in the FFR group (40. 
Outcomes
At 1 year, the primary end point (a composite of major adverse cardiac events) had occurred in 78 of 1148 patients (6.8%) in the iFR group and in 83 of 1182 patients (7.0%) in the FFR group (Fig. 2) . The hazard ratio was 0.95 (95% confidence interval [CI], 0.68 to 1.33; P = 0.78), and the difference in risk was −0.2 percentage points (95% CI, −2.3 to 1.8; 99% CI, −2.9 to 2.5; P = 0.83) ( Table 3, and Table S2 in the Supplementary Appendix). The upper limits of the twosided 95% and 99% confidence intervals were within the prespecified noninferiority margin of 3.4 percentage points (P<0.001 for noninferiority). The risks of each individual component of the primary end point and of death from cardiovascular or noncardiovascular causes did not differ significantly between the two groups.
The noninferiority of iFR to FFR was also confirmed in the per-protocol analysis (Tables  S4 and S5 in the Supplementary Appendix). In the per-protocol analysis, the hazard ratio for major adverse cardiac events was 0.94 (95% CI, 0.67 to 1.31; P = 0.72), and the difference in risk was −0.3 percentage points (95% CI, −2.4 to 1.8; 99% CI, −3.0 to 2.4; P = 0.77). The risk of each individual component of the composite end point did not differ significantly between the two groups in the per-protocol analyses.
Procedural Signs and Symptoms
In the iFR group, 39 patients (3.1%) reported adverse procedural symptoms or signs, including 19 who reported chest pain and 13 who reported dyspnea (Table 2 ). In the FFR group, 385 patients (30.8%) reported adverse procedural symptoms or signs, including 250 who reported dyspnea and 90 who reported chest pain. The difference between the two groups in the number of patients with adverse procedural symptoms or signs was significant (P<0.001) (Fig. S9 in the Supplementary Appendix). Serious adverse events (bronchospasm and ventricular arrhythmias) were reported in 8 patients in the FFR group (after hyperemia) and in 1 patient in the iFR group.
Discussion
In the DEFINE-FLAIR trial, we found that iFRguided coronary revascularization was noninferior to FFR-guided revascularization with respect to the risk of major adverse cardiac events. The use of iFR was also associated with a lower rate of procedural signs and symptoms and with a shorter procedural time than the use of FFR. There were no significant differences between the trial groups in the rates of death from any cause, death from cardiovascular causes, nonfatal myocardial infarction, and unplanned revascularization. These results suggest that the benefits of physiologically guided coronary revascularization with FFR can also be achieved with iFR. Our principal findings are similar to those now reported in the Journal by Götberg et al. 16 It has previously been proposed that a hybrid iFR-FFR approach might be advantageous for the detection of functionally significant stenoses, with iFR used as the initial measure and FFR used only to evaluate stenoses that were of intermediate severity on iFR-guided assessment. 17, 18 However, the results of our trial suggest that iFR alone can effectively identify stenoses that require intervention. Our trial also provides clinical evidence that there is no significant advantage to the administration of a hyperemic agent -a finding consistent with results of studies in which iFR and FFR were compared with other reference standards. 13, 14, 19, 20 Although evidence supporting the benefits of physiologically guided revascularization has accumulated over the past decade, adoption of this approach in clinical practice has lagged. There are many reasons for this, including equipment and drug costs, inadequate reimbursement, physician preferences, patient symptoms, and addi- tional procedural burden. Although adenosine is a generally safe drug that is used in millions of diagnostic procedures annually, its risks are well documented 21, 22 and it is not suitable for every patient; therefore, avoiding the use of adenosine is preferable. 11, 23, 24 In addition, adenosine contributes substantially to the cost of physiological stenosis assessment, and its use is hampered in many countries because it is unavailable or not indicated for this purpose. Thus, the ability to perform physiological assessments of coronaryartery stenoses without the use of adenosine may increase the use of such assessments in clinical practice. * Patients who had a myocardial infarction or an unplanned revascularization before withdrawing from the study were included in the analyses. † For the primary end point, the upper limit of the 95% confidence interval was 1.8 percentage points, which was within the prespecified noninferiority margin of 3.4 percentage points. Although the patients were not informed of their group assignments, adverse procedural symptoms or signs occurred in 30.8% of the patients in the FFR group, as compared with 3.1% of the patients in the iFR group. This difference is most likely due to the side effects of adenosine. It is therefore possible that at least some patients in the FFR group became aware of their group assignment. Such unblinding could have led to bias in the rates of unplanned revascularization, especially if patients discussed these symptoms with their physicians. The number of functionally significant stenoses was lower in the iFR group than in the FFR group. This difference could be a consequence of dissimilar thresholds for the two measures. In addition, iFR has been shown to be more closely linked to coronary flow reserve than FFR, and a previous study has shown higher revascularization rates associated with assessment guided by FFR than with assessment guided by coronary flow reserve. 25 Regardless of the explanation, the results of our trial suggest that the use of iFR can lead to outcomes similar to those associated with FFR and to the placement of fewer (potentially unnecessary) stents.
The clinical population in our trial differed from the population in the FAME trial (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation), in which all the patients had multivessel disease and were scheduled for revascularization. 6 In DEFINE-FLAIR, only 41% had multivessel disease. Although the benefit of coronary revascularization in patients with single-vessel disease is likely to be more uncertain, our trial population is probably similar to the population that would be seen in current clinical practice. Given the clinical evidence in support of physiologically guided revascularization, it was considered unethical to repeat a study similar to FAME, in which iFR-guided revascularization was compared with angiography-guided revascularization.
In our trial, the noninferiority margin for the difference in risk was set at 3.4 percentage points, which meant that the upper limit of the hazard ratio could have been as high as 1.40 while still allowing a claim of noninferiority. Although this noninferiority margin is wide, it is similar to margins used in other major clinical trials in cardiology. [26] [27] [28] [29] [30] [31] [32] The event rates were lower than had been expected, because the number of patients with an acute coronary syndrome who were enrolled in the trial was lower than had been anticipated. However, when we used the prespecified noninferiority margin to test the actual event rate among the prespecified number of patients, we found that iFR was noninferior to FFR even when the upper limit of a one-sided 99.5% confidence interval was used.
In conclusion, we found that coronary revascularization guided by iFR was noninferior to revascularization guided by FFR with respect to major adverse cardiac events at 1 year. The rate of adverse procedural signs or symptoms was lower and the procedure time was shorter in the iFR group than in the FFR group.
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